• LAST PRICE
    2.8200
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    2.5600/ 15
  • Ask / Lots
    3.0500/ 1
  • Open / Previous Close
    0.0000 / 2.8200
  • Day Range
    ---
  • 52 Week Range
    Low 2.5101
    High 4.5500
  • Volume
    1
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Tuesday's close: 2.88
TimeVolumeLUMO
10:39 ET2612.81
11:29 ET1002.93
11:44 ET1002.87
12:05 ET16502.8773
12:41 ET6592.86
12:50 ET4802.9399
01:57 ET9962.88
03:27 ET9302.95
03:36 ET1202.93
03:52 ET2002.81
03:57 ET1002.82
03:59 ET1002.82
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesLUMO
Lumos Pharma Inc
22.9M
-0.7x
---
United StatesADXN
Addex Therapeutics Ltd
19.8M
0.0x
---
United StatesSLGL
Sol Gel Technologies Ltd
27.3M
-1.0x
---
United StatesSNTI
Senti Biosciences Inc
17.8M
-0.2x
---
United StatesOCX
OncoCyte Corp
24.6M
-0.9x
---
United StatesONCT
Oncternal Therapeutics Inc
24.3M
-0.6x
---
As of 2024-03-28

Company Information

Lumos Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in advancing its clinical program and focused on identifying, acquiring, developing, and commercializing products and new therapies for people with rare diseases. Its pipeline is focused on the development of an orally administered small molecule, LUM-201, which is a growth hormone (GH) secretagogue, also called ibutamoren, for rare endocrine disorders that require injectable recombinant human growth hormone (rhGH). LUM-201 is a tablet formulation that is intended to be administered once daily. LUM-201 stimulates GH via the GH secretagogue receptor (GHSR1a), also known as the ghrelin receptor, and also suppresses the release of somatostatin, thus providing a differentiated mechanism of action to treat some rare endocrine disorders (involving a deficiency of GH) by increasing the amplitude of endogenous, pulsatile GH secretion. Lumos Pharma Sub, Inc. (Private Lumos) is its subsidiary.

Contact Information

Headquarters
4200 MARATHON BLVD., SUITE 200AUSTIN, TX, United States 78756
Phone
512-215-2630
Fax
515-296-3520

Executives

Chairman of the Board, Chief Executive Officer
Richard Hawkins
President, Chief Scientific Officer
John Mckew
Chief Financial Officer, Principal Accounting Officer
Lori Lawley
General Counsel
Bradley Powers
Chief Medical Officer
Pisit Pitukcheewanont

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$22.9M
Revenue (TTM)
$2.1M
Shares Outstanding
8.1M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.66
EPS
$-4.19
Book Value
$3.37
P/E Ratio
-0.7x
Price/Sales (TTM)
11.1
Price/Cash Flow (TTM)
---
Operating Margin
-1,785.18%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.